Journal of infectious diseases and treatment publishes positive trial data of aviptadil in high comorbidity patients suffering from critical covid-19 with respiratory failure

Radnor, pa., oct. 14, 2021 /prnewswire/ -- nrx pharmaceuticals (nasdaq: nrxp), today announced the publication of peer-reviewed results from a prospective, open-label, administratively controlled trial of aviptadil for the treatment of respiratory failure in patients with critical covid-19.
NRXP Ratings Summary
NRXP Quant Ranking